Original ArticlesLong-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents
Section snippets
Procedure
With institutional review board approval, we reviewed the medical records of all adolescents aged ≤19 years who initiated Depo-Provera between 1 December 1992 and 31 December 1995, at two clinics in New York City. The New York Hospital Women’s Health Clinic is an obstetrics and gynecology (Ob/Gyn) clinic serving primarily low-income women who reside in all five boroughs of New York City. Ob/Gyn residents and nurse practitioners provide care under the supervision of full-time faculty. There is
Study population
A total of 174 adolescent Depo-Provera users were identified. Two subjects who had used Depo-Provera before and 10 subjects who had initiated Depo-Provera while hospital inpatients or at outside sites were excluded, as were three subjects who initiated Depo-Provera while awaiting Norplant, leaving 159 first-time Depo-Provera users in the final study sample. Of these, 117 (73%) attended the hospital-based clinic and 42 (27%) attended the community-based clinic. Most (79%) had at some point
Discussion
This study imparts new information regarding long-term use of Depo-Provera among adolescents. Our findings confirm earlier reports that the rate of long-term Depo-Provera use among adolescents is low, with almost three quarters stopping the method within the first year of use. These findings are also similar to those for a population of adolescent mothers using Depo-Provera in Philadelphia, where 66% stopped Depo-Provera use within 1 year 22. As reported in previous studies, the majority of
Acknowledgements
This study was supported in part by a National Institutes of Health Short-Term Training Grant for Students in Health.
References (27)
- et al.
A preliminary report of Norplant implant insertions in a large urban family planning program
Contraception
(1993) - et al.
Contraceptive implant use among inner city teens
J Adolesc Health
(1995) - et al.
A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives
J Pediatr
(1996) - et al.
Medroxyprogesterone acetate (Depo-Provera) use in adolescentsUterine bleeding and blood pressure patterns, patient satisfaction and continuation rates
Adolesc Pediatr Gynecol
(1995) - et al.
Depo-Provera in adolescentsEffects of early second injection or prior oral contraception
J Adolesc Health
(1995) - et al.
Depot medroxyprogesterone acetate versus oral contraceptive use by post partum adolescents
Obstet Gynecol
(1998) - et al.
Subdermal implants (Norplant) continuation rates among adolescents and adults in a family planning clinic
J Pediatr Adol Gynecol
(1996) - et al.
Understanding the impact of effective teenage pregnancy prevention programs
Fam Plann Perspect
(1995) Adolescent pregnancy prevention programs
(1997)Risk of contraceptive discontinuation among adolescents
J Adolesc Health Care
(1989)
Adolescent’s compliance with the use of oral contraceptives
JAMA
Contraceptive failure rates in the United StatesRevised estimates from the 1982 National Survey of Family Growth
Fam Plann Perspect
Adolescents and condom use
Am J Dis Child
Cited by (67)
Use of Long-Acting Reversible Contraception (LARC) and the Depo-Provera Shot in Adolescents
2018, Current Problems in Pediatric and Adolescent Health CareBone Mineral Density and Weight Changes in Adolescents Randomized to 3 Doses of Depot Medroxyprogesterone Acetate
2017, Journal of Pediatric and Adolescent GynecologyProviding Contraception to Adolescents
2015, Obstetrics and Gynecology Clinics of North AmericaCitation Excerpt :The amenorrhea rate after 12 months of use is greater than 50%.62 Rates of discontinuation are high among adolescents; almost half will discontinue DMPA within 6 months of initiation.61,63 The most common reasons for discontinuation among adolescents are irregular bleeding and weight gain.61,63
Serum adipocytokines and adipose weight gain: A pilot study in adolescent females initiating depot medroxyprogesterone acetate
2015, ContraceptionCitation Excerpt :DMPA-associated weight gain is entirely composed of increases in total body fat mass [2,3]. To date, clinical characteristics such as race and obesity status have not been found to consistently predict DMPA-associated weight gain [4–7]. Weight gain at 6 months has been shown to be the best predictor of continued excessive weight gain.
Dietary Intake and Weight Gain Among Adolescents on Depot Medroxyprogesterone Acetate
2015, Journal of Pediatric and Adolescent Gynecology